Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijrobp.2012.03.001PMID 22658512
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.

  2011cited by this paper
• Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

  2010cited by this paper
• Why are pretreatment prostate‐specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

  2009cited by this paper
• Intermittent androgen blockade should be regarded as standard therapy in prostate cancer

  2008cited by this paper
• Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.

  2007cited by this paper
• Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

  2006cited by this paper
• How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.

  2006cited by this paper
• Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

  2006cited by this paper
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

  2006cited by this paper
• Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Andropause: symptom management for prostate cancer patients treated with hormonal ablation.

  2003cited by this paper
• Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

  2003cited by this paper
• Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias.

  2003cited by this paper
• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

  2002cited by this paper
• Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer.

  2002cited by this paper
• Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

  1997cited by this paper
• Consensus statement: Guidelines for PSA following radiation therapy

  1997cited by this paper
• Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.

  1997cited by this paper
• Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.

  1997cited by this paper
• Analysis of Binary Data (2nd ed.).

  1990cited by this paper
• The analysis of binary data

  1971cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Early Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature

  2025cites this paper
• Significant Effect of Carbon‐Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High‐Risk Prostate Cancer Patients: A Two‐Center Controlled Trial Compare With X‐Ray External Beam Radiation Therapy

  2024cites this paper
• First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.

  2022cites this paper
• Perioperative therapies for urological cancers.

  2020cites this paper
• ADT in Combination with Radiation Therapy for Clinically Localized Prostate Cancer

  2018cites this paper
• ADT as Salvage Therapy After Definitive Treatment for Clinically Localized Prostate Cancer

  2018cites this paper
• Evidenced‐based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition)

  2017cites this paper
• Cancer‐specific mortality of high‐risk prostate cancer after carbon‐ion radiotherapy plus long‐term androgen deprivation therapy

  2017cites this paper
• Fundamentals of Radiation Treatment for Prostate Carcinoma – Techniques, Radiation Biology, and Evidence Base

  2016cites this paper
• Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer

  2016cites this paper
• The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer.

  2016cites this paper
• Significant impact of biochemical recurrence on overall mortality in patients with high‐risk prostate cancer after carbon‐ion radiotherapy combined with androgen deprivation therapy

  2016cites this paper
• Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer

  2016cites this paper
• Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology

  2015cites this paper
• Intensity-Modulated Radiation Therapy for Locally Advanced Prostate Cancer

  2015cites this paper
• Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.

  2015cites this paper
• Role of 3.0 T multiparametric MRI in local staging in prostate cancer and clinical implications for radiation oncology

  2014cites this paper
• Medical treatment for biochemical relapse after radiotherapy.

  2014cites this paper
• Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy

  2014influential citation
• Detecting prostate cancer metastases - PET/CT and the sentinel node technique

  2014cites this paper
• PET/CT and the sentinel node technique

  2014cites this paper
• Guidelines on Prostate Cancer

  2013cites this paper
• Oncology scan--intermittent androgen deprivation and the randomized evidence.

  2013cites this paper
• Vaginal approaches to pelvic organ prolapse repair

  2013cites this paper
• Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review.

  2013cites this paper